AKRO Akero Therapeutics Inc

Price (delayed)

$28.08

Market cap

$976.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.52

Enterprise value

$790.62M

Sector: Healthcare
Industry: Biotechnology

Highlights

AKRO's debt is down by 3.1% since the previous quarter
AKRO's equity has surged by 101% year-on-year but it is down by 10% since the previous quarter
Akero Therapeutics's quick ratio has increased by 41% YoY but it has decreased by 16% QoQ
AKRO's net income has shrunk by 81% YoY and by 22% QoQ

Key stats

What are the main financial stats of AKRO
Market
Shares outstanding
34.77M
Market cap
$976.35M
Enterprise value
$790.62M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.77
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$79.21M
EBITDA
-$78.99M
Free cash flow
-$70.95M
Per share
EPS
-$2.52
Free cash flow per share
-$2.26
Book value per share
$7.45
Revenue per share
$0
TBVPS
$8.69
Balance sheet
Total assets
$273.34M
Total liabilities
$14.63M
Debt
$1.52M
Equity
$258.71M
Working capital
$258.23M
Liquidity
Debt to equity
0.01
Current ratio
20.7
Quick ratio
20.47
Net debt/EBITDA
2.35
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-38.9%
Return on equity
-41.3%
Return on invested capital
-112%
Return on capital employed
-30.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKRO stock price

How has the Akero Therapeutics stock price performed over time
Intraday
1.26%
1 week
2.74%
1 month
2.82%
1 year
24.74%
YTD
8.84%
QTD
-3.21%

Financial performance

How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$80.15M
Net income
-$79.21M
Gross margin
N/A
Net margin
N/A
AKRO's net income has shrunk by 81% YoY and by 22% QoQ
Akero Therapeutics's operating income has plunged by 76% YoY and by 20% from the previous quarter

Growth

What is Akero Therapeutics's growth rate over time

Valuation

What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
3.77
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has decreased by 35% QoQ but it has increased by 13% YoY
AKRO's equity has surged by 101% year-on-year but it is down by 10% since the previous quarter
The stock's P/B is 23% below its last 4 quarters average of 4.8

Efficiency

How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on invested capital has surged by 65% YoY but it has decreased by 17% QoQ
The ROA has contracted by 16% YoY
Akero Therapeutics's return on equity has increased by 11% YoY

Dividends

What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKRO.

Financial health

How did Akero Therapeutics financials performed over time
The company's total assets has surged by 98% YoY but it fell by 9% QoQ
The total liabilities has soared by 56% year-on-year and by 8% since the previous quarter
AKRO's debt is 99% smaller than its equity
AKRO's equity has surged by 101% year-on-year but it is down by 10% since the previous quarter
AKRO's debt is down by 3.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.